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Dear Sir,
Our group from Pamukkale University Hospital would
like to present an observation on hemoptysis that was prob-
ably associated with sildenafil usage in two patients.  Since
hemoptysis occurred immediately the drug was taken and
has not recurred following the discontinuation of the drug.
We think that after eliminating other risk factors, sildenafil
might be a probable cause of transient hemoptysis.
Case 1
A 70-year-old male patient presented to the Chest
Diseases Department at the Pamukkale University School
of Medicine with a complaint of a bloody cough for
2 days.  There were no other symptoms.  He had no
chronic bronchitis or any other accompanying diseases
except benign prostatic hyperplasia.  He had been a heavy
smoker, and had a 50-pack/year hisory.  His physical
examination and routine laboratory evaluation, including
chest X-ray, pulmonary function tests and bleeding tests,
were normal.  Although he denied having taken any drugs
at that period, his daughter stated that she incidentally
observed that he used sildenafil blister.  Because no rela-
tionship between hemoptysis and sildenafil usage has been
reported previously, the patient was treated with antitus-
sive and antifibrinolytic (tranexamic acid, perorally,
250 mg t.i.d) for 1 week.  The hemoptysis was cleared
up.  One month after the first admission, the patient rep-
resented to the chest clinic with a recurrence of
hemoptysis.  No abnormality was detected in a compre-
hensive systemic evaluation or during the physical
examination.  The routine laboratory analysis and bleed-
ing tests were still within normal ranges.  Microbiologi-
cal analysis of sputum showed normal upper airway flora
and negative acid-fast bacillus staining.  The sputum
cytology was benign.  Because of the patient’s previous
history, sildenafil usage was questioned and a recent in-
take at the same day of hemoptysis was determined.
Thorax computed tomography (CT) revealed ground
glass attenuation in left upper zone, and control CT
imaging on the seventh day after the first CT scan
showed complete clearance of that diagnosis.  The pa-
tient has refused to have a bronchoscopy and has been
treated with the same medications as previously.  He was
warned about the possible side-effects of sildenafil.
During the 24-month follow-up, the patient was fine,
with no recurrence of hemoptysis or pulmonary
complaints, and he declared that he did not  use sildenafil
any more during that period.
Case 2
Another male patient aged 55 years has presented to
Thoracic Surgery Department at the Pamukkale Univer-
sity School of Medicine with a minimum blood-staining
of sputum.  During detailed questioning, it was revealed
that the patient had recently used 50 mg sildenafil along
with alcohol on the same day as hemoptysis occurred.




There were no accompanying diseases, including chronic
bronchitis.  Although the patient was a smoker, his de-
tailed smoking history was not taken.  No abnormality
was detected in the comprehensive systemic evaluation
and physical examination.  The pulmonary function tests,
routine laboratory analysis and bleeding tests were in nor-
mal ranges.  The sputum cytology was benign and acid-
fast bacille staining of sputum was negative.  There were
no radiological abnormalities in either chest X-ray or tho-
rax CT.  The patient was warn about the possible side-
effects of sildenafil usage and recovered spontaneously.
During the 16-month follow-up, the patient was fine,
with no recurrence of hemoptysis or pulmonary
complaints, and he declared that he did not use any more
sildenafil during the follow-up period.
The introduction of sildenafil citrate, the first effec-
tive and safe oral agent for erectile dysfunction (ED),
has led to major changes in ED management and thus
widespread use of this medication worldwide [1].  When
patients voluntarily use sildenafil citrate but deny that they
have used the drug, the management of medical prob-
lems becomes complicated, particularly if the associa-
tion of symptoms of the drug use has not been observed
before.  To our knowledge, we present the first two cases
of hemoptysis observed just after sildenafil usage in pa-
tients with no other risk factors.
According to Son et al. [2] approximately 50% of
those treated with PDE5 inhibitors discontinued their
treatment.  The reasons for discontinuing sildenafil medi-
cation after successful treatment were primarily emo-
tional or relationship-oriented, which indicates that simple
recovery of a rigid erection is insufficient to restore sexual
activity [3].  Although treatment-related adverse events
for all doses occurred more frequently in sildenafil-treated
patients than in placebo-treated patients, only a few cases
have been described of serious adverse cardiovascular
events leading discontinuation [4, 5].  According to clini-
cal trial reports for specific adverse events, flushing (12%
of patients), headache (11% of patients), dyspepsia (5%
of patients) and visual disturbances (3% of patients)
occurred, and the incidence of these events all increased
with doses [4, 5].  Hemoptysis is not an adverse effect
that has been previously reported with sildenafil treatment.
The etiology of hemoptysis could not be explained
with a pulmonary disorder in our patients.  The most
frequent causes of hemoptysis are malignancies, bron-
chiectasis and tuberculosis.  Each patient underwent rig-
orous historical questioning, comprehensive physical
examination and systemic workup to rule out those known
causes of hemoptysis and to determine contributing
factors.  No risk factors were found.  Smoking might
lead to hemoptysis, but hemoptysis developed in both
patients soon after use of sildenafil and has not recurred
again following the discontinuation of the drug.  Two
similar occasions after sildenafil usage in our first case
might be considered as support of our hypothesis.
Moreover, neither of the cases experienced hemoptysis
after ceasing to use sildenafil and neither had specific
pulmonary diagnosis on follow up.  Therefore, we hy-
pothesize that sildenafil might have induced hemoptysis
in our patients.  Sildenafil selectively inhibits PDE5, which
is abundant in pulmonary and penile tissue.  This results
in increasing nitric oxide at tissue level, leading to pul-
monary dilatation [6].  Increased vasodilatation of the
pulmonary vascular system, including pulmonary
capillaries, might be the cause of hemoptysis.  Although
there is no exact cause or effect relationship, our obser-
vations could alert physicians to question patients about
the use of sildenafil in cases of idiopathic hemoptysis.
More than 20 million patients have been treated with
sildenafil citrate for ED.  Therefore, sildenafil is one of the
most widely studied drugs effective in ED and generally
well tolerated [1].  However, we would like to emphasize
that sildenafil treatment might be a probable cause of tran-
sient hemoptysis after eliminating other risk factors.
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